343 Shares in Revvity, Inc. (NYSE:RVTY) Bought by Desjardins Global Asset Management Inc.

Desjardins Global Asset Management Inc. purchased a new position in Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 343 shares of the company’s stock, valued at approximately $37,000.

Several other large investors also recently bought and sold shares of the business. Gladius Capital Management LP increased its position in Revvity by 84.1% in the third quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares during the last quarter. CENTRAL TRUST Co bought a new position in Revvity during the fourth quarter valued at $27,000. ORG Partners LLC bought a new position in Revvity during the fourth quarter valued at $32,000. JTC Employer Solutions Trustee Ltd bought a new position in Revvity during the fourth quarter valued at $33,000. Finally, Headinvest LLC bought a new position in Revvity during the third quarter valued at $57,000. Institutional investors own 86.65% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on RVTY shares. Stifel Nicolaus upped their price target on shares of Revvity from $95.00 to $110.00 and gave the stock a “hold” rating in a report on Friday, February 2nd. Evercore ISI upgraded shares of Revvity from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $88.00 to $125.00 in a report on Thursday, January 4th. UBS Group cut shares of Revvity from a “buy” rating to a “neutral” rating and upped their price target for the stock from $105.00 to $125.00 in a report on Tuesday, January 16th. KeyCorp upped their price target on shares of Revvity from $110.00 to $126.00 and gave the stock an “overweight” rating in a report on Friday, February 2nd. Finally, Raymond James upped their price target on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $118.91.

Revvity Stock Up 1.5 %

NYSE:RVTY opened at $100.86 on Friday. The firm has a market cap of $12.46 billion, a PE ratio of 18.34, a price-to-earnings-growth ratio of 2.62 and a beta of 1.09. The company has a 50-day moving average of $104.78 and a 200 day moving average of $101.64. Revvity, Inc. has a 1-year low of $79.50 and a 1-year high of $135.67. The company has a debt-to-equity ratio of 0.40, a current ratio of 2.07 and a quick ratio of 1.77.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Thursday, February 1st. The company reported $1.25 EPS for the quarter, beating the consensus estimate of $1.15 by $0.10. The business had revenue of $695.90 million during the quarter. Revvity had a net margin of 25.20% and a return on equity of 7.41%. As a group, research analysts anticipate that Revvity, Inc. will post 4.65 EPS for the current fiscal year.

Revvity Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 10th. Investors of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a dividend yield of 0.28%. The ex-dividend date is Thursday, April 18th. Revvity’s payout ratio is currently 5.09%.

Insider Activity at Revvity

In related news, insider Prahlad R. Singh sold 21,217 shares of the stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.60% of the stock is currently owned by insiders.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.